Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 3/20 | 0.40 |
| ▸ | OGA | O60502 | 7/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4708914 | 1.00 | MAPT (0.40) | MAPTSMN1; SMN2ACACBOGAMAPK1 | |
| SCHEMBL4711640 | 0.88 | OGA (0.43) | MAPTSMN1; SMN2ACACBOGAMAPK1 | |
| SCHEMBL4709291 | 0.87 | MAPT (0.40) | MAPTSMN1; SMN2ACACBOGAMAPK1 | |
| SCHEMBL4709294 | 0.87 | MAPT (0.40) | MAPTSMN1; SMN2ACACBOGAMAPK1 | |
| SCHEMBL4710513 | 0.84 | HIF1A (0.41) | ACACBOGAMAPK1HIF1AUTS2R | |
| SCHEMBL4710443 | 0.84 | MAPT (0.47) | MAPTSMN1; SMN2ACACBOGAHIF1A | |
| SCHEMBL5524464 | 0.84 | MAPT (0.47) | MAPTSMN1; SMN2ACACBOGAHIF1A | |
| SCHEMBL4709595 | 0.84 | MAPT (0.47) | MAPTSMN1; SMN2ACACBOGAHIF1A | |
| SCHEMBL4711886 | 0.81 | OGA (0.43) | MAPTSMN1; SMN2OGAMAPK1HIF1A | |
| SCHEMBL4708805 | 0.79 | OGA (0.48) | MAPTACACBOGAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935885-A2 | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. | NEUROGEN CORPORATION (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080044353-A1 | Combination Therapy for Weight Management | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-7241765-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060229298-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | HUTCHISON ALAN | 2006-10-12 | — | — | US | disclosed |
| US-7081458-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORP. (US) | 2006-07-25 | — | — | US | disclosed |
| US-6953801-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050182068-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | HUTCHISON ALAN (US) | 2005-08-18 | — | — | US | disclosed |
| US-20050065162-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044353-A1 | Combination Therapy for Weight Management | CNR1, CNR2, MCHR1 | MAPT 3153/4885SMN1; SMN2 1643/4885ACACB 987/4885 |
| US-20060229298-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | MCHR1, MCHR2, MC1R | MAPT 2914/4885SMN1; SMN2 1441/4885ACACB 4622/4885 |
| US-20050065162-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | MCHR1, MCHR2, MC1R | MAPT 2914/4885SMN1; SMN2 1441/4885ACACB 4622/4885 |
| US-20050182068-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | MCHR1, MCHR2, MC1R | MAPT 2914/4885SMN1; SMN2 1441/4885ACACB 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.